Movers and SHAKERS
Dyadic International Inc. (DYAI)
Confidence in 2020 Outlook
Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the industrially proven hyper productive engineered fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1.
The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and improve access and cost to patients and the healthcare system, but most importantly save lives.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Expanded research collaborations in Q4 2019. Dyadic expanded research collaboration with Zoonoses Anticipation and Preparedness Initiative (ZAPI) to express two additional proteins based on the preliminary results from animal studies. In addition, Dyadic entered into a new collaboration with a pharmaceutical company (in the top ten) expanding its portfolio to six proof of concept research collaborations. Lastly, a research license agreement was established with an affiliate of a current research collaborator (a top 25 pharmaceutical company) to further evaluate C1 technology with the objective of broadening and accelerating the adoption and use of C1 globally.
Presentations during the JPM healthcare conference. Dyadic’s management team continues to be proactive and open to meet with collaborators and investors. There will be few presentations by the management during JP Morgan including i) BFC Global Healthcare Investment Conference at 2:30 p.m. PST on January 12, Sunday, ii) China Focus at 10:50 a.m. PST on January 12, Sunday, and iii) Biotech Showcase at...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.